Trial Outcomes & Findings for Neuroimaging Study of Dexmedetomidine-Induced Analgesia (NCT NCT04656470)
NCT ID: NCT04656470
Last Updated: 2026-04-23
Results Overview
Transient waves of CSF inflow
Recruitment status
COMPLETED
Study phase
PHASE2/PHASE3
Target enrollment
17 participants
Primary outcome timeframe
During imaging scan
Results posted on
2026-04-23
Participant Flow
Institutional email announcing ongoing studies
Participant milestones
| Measure |
Dexmedetomidine
During the study visit, patients will be delivered dexmedetomidine anesthesia. 0.5mcg/kg of dexmedetomidine solution will be infused over 10 minutes, and then up to 0.5mcg/kg/hr will be maintained for an additional 20-30 minutes.
|
|---|---|
|
Overall Study
STARTED
|
17
|
|
Overall Study
COMPLETED
|
5
|
|
Overall Study
NOT COMPLETED
|
12
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Neuroimaging Study of Dexmedetomidine-Induced Analgesia
Baseline characteristics by cohort
| Measure |
Dexmedetomidine
n=5 Participants
During the study visit, patients will be delivered dexmedetomidine anesthesia. 0.5mcg/kg of dexmedetomidine solution will be infused over 10 minutes, and then up to 0.5mcg/kg/hr will be maintained for an additional 20-30 minutes.
|
|---|---|
|
Age, Categorical
<=18 years
|
0 Participants
n=60 Participants
|
|
Age, Categorical
Between 18 and 65 years
|
5 Participants
n=60 Participants
|
|
Age, Categorical
>=65 years
|
0 Participants
n=60 Participants
|
|
Sex: Female, Male
Female
|
3 Participants
n=60 Participants
|
|
Sex: Female, Male
Male
|
2 Participants
n=60 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=60 Participants
|
|
Race (NIH/OMB)
Asian
|
0 Participants
n=60 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=60 Participants
|
|
Race (NIH/OMB)
Black or African American
|
0 Participants
n=60 Participants
|
|
Race (NIH/OMB)
White
|
2 Participants
n=60 Participants
|
|
Race (NIH/OMB)
More than one race
|
2 Participants
n=60 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
1 Participants
n=60 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
0 Participants
n=60 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
4 Participants
n=60 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
1 Participants
n=60 Participants
|
|
Region of Enrollment
United States
|
5 Participants
n=60 Participants
|
PRIMARY outcome
Timeframe: During imaging scanTransient waves of CSF inflow
Outcome measures
| Measure |
Dexmedetomidine
n=5 Participants
During the study visit, patients will be delivered dexmedetomidine anesthesia. 0.5mcg/kg of dexmedetomidine solution will be infused over 10 minutes, and then up to 0.5mcg/kg/hr will be maintained for an additional 20-30 minutes.
|
|---|---|
|
CSF Flow Measured in Hz
|
-15 Hz
Standard Deviation 5
|
Adverse Events
Dexmedetomidine
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place